PubMed:26930132 JSON TXT

Annnotations TAB JSON ListView MergeView

sentences

Preeclampsia

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":0,"end":12},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":30,"end":42},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":222,"end":234},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":252,"end":264},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":665,"end":677},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T6","span":{"begin":695,"end":707},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T7","span":{"begin":816,"end":828},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T8","span":{"begin":846,"end":858},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T9","span":{"begin":925,"end":937},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T10","span":{"begin":1470,"end":1482},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T11","span":{"begin":1647,"end":1659},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T12","span":{"begin":1713,"end":1725},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.\nOBJECTIVE: We aimed to compare sFlt-1 and placental growth factor (PlGF) levels and the sFlt-1/PlGF ratio between women with preeclampsia and superimposed preeclampsia to, respectively, normotensive and chronic hypertensive ones.\nSTUDY DESIGN: We performed a prospective two-armed cohort in a tertiary teaching hospital in Sao Paulo, Brazil, including 37 normotensive and 60 chronic hypertensive pregnant women. We assessed the serum levels of sFlt-1 and PlGF at 20, 26, 32, and 36 gestational weeks by enzyme-linked immunosorbent assay.\nMAIN OUTCOME MEASURES: Having preeclampsia and superimposed preeclampsia.\nRESULTS: Among normotensive and chronic hypertensive pregnancies, 4 (10.8%) and 14 (23.3%) women developed preeclampsia and superimposed preeclampsia, respectively. Compared with those who remained normotensive, the preeclampsia women presented higher sFlt-1 levels at 32 gestational weeks (4323.45 pg/mL vs. 2242.04 pg/mL, p = 0.019), lower PlGF levels at 20 (183.54 pg/mL vs. 337.38 pg/mL, p = 0.034), 32 (169.69 pg/mL vs. 792.53 pg/mL, p = 0.001), and 36 gestational weeks (252.99 pg/mL vs. 561.81 pg/mL, p = 0.029), and higher sFlt-1/PlGF ratios at 26 (9.02 vs. 1.84, p = 0.004), 32 (23.61 vs. 2.55, p = 0.001), and 36 gestational weeks (49.02 vs. 7.34, p = 0.029). On the other hand, compared with those who remained chronic hypertensive, the superimposed preeclampsia women only presented a higher sFlt-1/PlGF ratio at 32 gestational weeks (9.98 vs. 2.51, p = 0.039).\nCONCLUSION: Although angiogenic imbalance is clearly related to preeclampsia, it seems to play a more modest role in superimposed preeclampsia, in which other mechanisms should also be investigated."}

Preeclampsia-compare

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T1","span":{"begin":0,"end":12},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T2","span":{"begin":30,"end":42},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T3","span":{"begin":222,"end":234},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T4","span":{"begin":252,"end":264},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T5","span":{"begin":665,"end":677},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T6","span":{"begin":695,"end":707},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T7","span":{"begin":816,"end":828},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T8","span":{"begin":846,"end":858},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T9","span":{"begin":925,"end":937},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T10","span":{"begin":1470,"end":1482},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T11","span":{"begin":1647,"end":1659},"obj":"ORPHA:275555"},{"id":"PD-Preeclampsia-B_T12","span":{"begin":1713,"end":1725},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.\nOBJECTIVE: We aimed to compare sFlt-1 and placental growth factor (PlGF) levels and the sFlt-1/PlGF ratio between women with preeclampsia and superimposed preeclampsia to, respectively, normotensive and chronic hypertensive ones.\nSTUDY DESIGN: We performed a prospective two-armed cohort in a tertiary teaching hospital in Sao Paulo, Brazil, including 37 normotensive and 60 chronic hypertensive pregnant women. We assessed the serum levels of sFlt-1 and PlGF at 20, 26, 32, and 36 gestational weeks by enzyme-linked immunosorbent assay.\nMAIN OUTCOME MEASURES: Having preeclampsia and superimposed preeclampsia.\nRESULTS: Among normotensive and chronic hypertensive pregnancies, 4 (10.8%) and 14 (23.3%) women developed preeclampsia and superimposed preeclampsia, respectively. Compared with those who remained normotensive, the preeclampsia women presented higher sFlt-1 levels at 32 gestational weeks (4323.45 pg/mL vs. 2242.04 pg/mL, p = 0.019), lower PlGF levels at 20 (183.54 pg/mL vs. 337.38 pg/mL, p = 0.034), 32 (169.69 pg/mL vs. 792.53 pg/mL, p = 0.001), and 36 gestational weeks (252.99 pg/mL vs. 561.81 pg/mL, p = 0.029), and higher sFlt-1/PlGF ratios at 26 (9.02 vs. 1.84, p = 0.004), 32 (23.61 vs. 2.55, p = 0.001), and 36 gestational weeks (49.02 vs. 7.34, p = 0.029). On the other hand, compared with those who remained chronic hypertensive, the superimposed preeclampsia women only presented a higher sFlt-1/PlGF ratio at 32 gestational weeks (9.98 vs. 2.51, p = 0.039).\nCONCLUSION: Although angiogenic imbalance is clearly related to preeclampsia, it seems to play a more modest role in superimposed preeclampsia, in which other mechanisms should also be investigated."}

preeclampsia_genes

{"project":"preeclampsia_genes","denotations":[{"id":"PD-PreeclampsiaGenes-B_T1","span":{"begin":139,"end":162},"obj":"HGNC:PGF"}],"text":"Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.\nOBJECTIVE: We aimed to compare sFlt-1 and placental growth factor (PlGF) levels and the sFlt-1/PlGF ratio between women with preeclampsia and superimposed preeclampsia to, respectively, normotensive and chronic hypertensive ones.\nSTUDY DESIGN: We performed a prospective two-armed cohort in a tertiary teaching hospital in Sao Paulo, Brazil, including 37 normotensive and 60 chronic hypertensive pregnant women. We assessed the serum levels of sFlt-1 and PlGF at 20, 26, 32, and 36 gestational weeks by enzyme-linked immunosorbent assay.\nMAIN OUTCOME MEASURES: Having preeclampsia and superimposed preeclampsia.\nRESULTS: Among normotensive and chronic hypertensive pregnancies, 4 (10.8%) and 14 (23.3%) women developed preeclampsia and superimposed preeclampsia, respectively. Compared with those who remained normotensive, the preeclampsia women presented higher sFlt-1 levels at 32 gestational weeks (4323.45 pg/mL vs. 2242.04 pg/mL, p = 0.019), lower PlGF levels at 20 (183.54 pg/mL vs. 337.38 pg/mL, p = 0.034), 32 (169.69 pg/mL vs. 792.53 pg/mL, p = 0.001), and 36 gestational weeks (252.99 pg/mL vs. 561.81 pg/mL, p = 0.029), and higher sFlt-1/PlGF ratios at 26 (9.02 vs. 1.84, p = 0.004), 32 (23.61 vs. 2.55, p = 0.001), and 36 gestational weeks (49.02 vs. 7.34, p = 0.029). On the other hand, compared with those who remained chronic hypertensive, the superimposed preeclampsia women only presented a higher sFlt-1/PlGF ratio at 32 gestational weeks (9.98 vs. 2.51, p = 0.039).\nCONCLUSION: Although angiogenic imbalance is clearly related to preeclampsia, it seems to play a more modest role in superimposed preeclampsia, in which other mechanisms should also be investigated."}

UBERON-AE

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":372,"end":377},"obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":525,"end":530},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.\nOBJECTIVE: We aimed to compare sFlt-1 and placental growth factor (PlGF) levels and the sFlt-1/PlGF ratio between women with preeclampsia and superimposed preeclampsia to, respectively, normotensive and chronic hypertensive ones.\nSTUDY DESIGN: We performed a prospective two-armed cohort in a tertiary teaching hospital in Sao Paulo, Brazil, including 37 normotensive and 60 chronic hypertensive pregnant women. We assessed the serum levels of sFlt-1 and PlGF at 20, 26, 32, and 36 gestational weeks by enzyme-linked immunosorbent assay.\nMAIN OUTCOME MEASURES: Having preeclampsia and superimposed preeclampsia.\nRESULTS: Among normotensive and chronic hypertensive pregnancies, 4 (10.8%) and 14 (23.3%) women developed preeclampsia and superimposed preeclampsia, respectively. Compared with those who remained normotensive, the preeclampsia women presented higher sFlt-1 levels at 32 gestational weeks (4323.45 pg/mL vs. 2242.04 pg/mL, p = 0.019), lower PlGF levels at 20 (183.54 pg/mL vs. 337.38 pg/mL, p = 0.034), 32 (169.69 pg/mL vs. 792.53 pg/mL, p = 0.001), and 36 gestational weeks (252.99 pg/mL vs. 561.81 pg/mL, p = 0.029), and higher sFlt-1/PlGF ratios at 26 (9.02 vs. 1.84, p = 0.004), 32 (23.61 vs. 2.55, p = 0.001), and 36 gestational weeks (49.02 vs. 7.34, p = 0.029). On the other hand, compared with those who remained chronic hypertensive, the superimposed preeclampsia women only presented a higher sFlt-1/PlGF ratio at 32 gestational weeks (9.98 vs. 2.51, p = 0.039).\nCONCLUSION: Although angiogenic imbalance is clearly related to preeclampsia, it seems to play a more modest role in superimposed preeclampsia, in which other mechanisms should also be investigated."}

performance-test

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":525,"end":530},"obj":"http://purl.obolibrary.org/obo/UBERON_0001977"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":139,"end":148},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":372,"end":377},"obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.\nOBJECTIVE: We aimed to compare sFlt-1 and placental growth factor (PlGF) levels and the sFlt-1/PlGF ratio between women with preeclampsia and superimposed preeclampsia to, respectively, normotensive and chronic hypertensive ones.\nSTUDY DESIGN: We performed a prospective two-armed cohort in a tertiary teaching hospital in Sao Paulo, Brazil, including 37 normotensive and 60 chronic hypertensive pregnant women. We assessed the serum levels of sFlt-1 and PlGF at 20, 26, 32, and 36 gestational weeks by enzyme-linked immunosorbent assay.\nMAIN OUTCOME MEASURES: Having preeclampsia and superimposed preeclampsia.\nRESULTS: Among normotensive and chronic hypertensive pregnancies, 4 (10.8%) and 14 (23.3%) women developed preeclampsia and superimposed preeclampsia, respectively. Compared with those who remained normotensive, the preeclampsia women presented higher sFlt-1 levels at 32 gestational weeks (4323.45 pg/mL vs. 2242.04 pg/mL, p = 0.019), lower PlGF levels at 20 (183.54 pg/mL vs. 337.38 pg/mL, p = 0.034), 32 (169.69 pg/mL vs. 792.53 pg/mL, p = 0.001), and 36 gestational weeks (252.99 pg/mL vs. 561.81 pg/mL, p = 0.029), and higher sFlt-1/PlGF ratios at 26 (9.02 vs. 1.84, p = 0.004), 32 (23.61 vs. 2.55, p = 0.001), and 36 gestational weeks (49.02 vs. 7.34, p = 0.029). On the other hand, compared with those who remained chronic hypertensive, the superimposed preeclampsia women only presented a higher sFlt-1/PlGF ratio at 32 gestational weeks (9.98 vs. 2.51, p = 0.039).\nCONCLUSION: Although angiogenic imbalance is clearly related to preeclampsia, it seems to play a more modest role in superimposed preeclampsia, in which other mechanisms should also be investigated."}